Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?

DOI: 10.1177/1352458517728811
Multiple Sclerosis Journal, 2018, 24, 1543-1556.

#	Paper	IF	Citations
28	Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. *Nature Communications*, **2017**, 8, 1990	17.4	31
27	Aktuelle Therapien und Zukunftsoptionen f□die progrediente Multiple Sklerose. *InFo Neurologie & Psychiatrie*, **2018**, 20, 28-36	0	1
26	Much, if not all, of the cortical damage in MS can be attributed to the microglial cell - Yes. *Multiple Sclerosis Journal*, **2018**, 24, 895-896	5	5
25	Microglia and CNS Interleukin-1: Beyond Immunological Concepts. *Frontiers in Neurology*, **2018**, 9, 8	4.1	77
24	Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. *Nature Reviews Drug Discovery*, **2019**, 18, 905-922	64.1	137
23	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. *Frontiers in Neurology*, **2019**, 10, 695	4.1	3
22	Progressive multiple sclerosis: latest therapeutic developments and future directions. *Therapeutic Advances in Neurological Disorders*, **2019**, 12, 1756286419878323	6.6	29
21	Matrix metalloproteinases in the CNS: interferons get nervous. *Cellular and Molecular Life Sciences*, **2019**, 76, 3083-3095	10.3	22
20	Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e551	9.1	10
19	Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. *Brain*, **2019**, 142, 133-145	11.2	69
18	Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation. *Lancet Neurology, The*, **2020**, 19, 1023-1032	24.1	39
17	Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis. *Metabolic Brain Disease*, **2020**, 35, 1299-1307	3.9	7
16	Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. *Expert Review of Neurotherapeutics*, **2021**, 21, 35-43	4.3	3
15	Effects of minocycline on motor function recovery and expression of glial fibrillary acidic protein and brain-derived neurotrophic factor after spinal cord injury in rats. *Journal of Pharmacy and Pharmacology*, **2021**, 73, 332-337	4.8	0
14	Clozapine Regulates Microglia and Is Effective in Chronic Experimental Autoimmune Encephalomyelitis. *Frontiers in Immunology*, **2021**, 12, 656941	8.4	5
13	Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020. *Drugs*, **2021**, 81, 1031-1063	12.1	7
12	Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. *Metabolic Brain Disease*, **2021**, 36, 2101-2110	3.9	0

11	Hydroxychloroquine for Primary Progressive Multiple Sclerosis. *Annals of Neurology*, **2021**, 90, 940-948	9.4	5
10	Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. *Therapeutic Advances in Neurological Disorders*, **2021**, 14, 17562864211035542	6.6	3
9	Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. *Nature Reviews Neurology*, **2021**,	15	3
8	A Distinct Extract Prevents Iron Neurotoxicity, a Driver of Multiple Sclerosis Pathology.. *Cells*, **2022**, 11,	7.9	2
7	Revisiting Minocycline in Intracerebral Hemorrhage: Mechanisms and Clinical Translation.. *Frontiers in Immunology*, **2022**, 13, 844163	8.4	0
6	Microglia in multiple sclerosis pathogenesis and imaging. *Current Opinion in Neurology*, **2022**, 35, 299-306	7.1	1
5	The potential use of tetracyclines in neurodegenerative diseases and the role of nano-based drug delivery systems. *European Journal of Pharmaceutical Sciences*, **2022**, 175, 106237	5.1	0
4	Microglia in multiple sclerosis: Protectors turn destroyers. *Neuron*, **2022**,	13.9	1
3	Positive effect of immunomodulatory therapies on disease progression in Huntington disease? Data from a real-world cohort. **2022**, 15, 175628642211097		0
2	Expression of antioxidant enzymes in lesions of multiple sclerosis and its models. **2022**, 12,		
1	The reciprocal interactions between microglia and T cells in Parkinson disease: a double-edged sword. **2023**, 20,		1